Marksans Pharma intimates of USFDA inspection of its manufacturing facility at Goa

Receives 4 observations under Form 483

Marksans Pharma announced that the United States Food & Drug Administration inspected its manufacturing facility located at Goa from 03 April to 07 April 2017. At the end of the inspections, there were 4 (four) observations given under Form 483. The company is already addressing the same and is confident of satisfying the FDA within stipulated time.

Powered by Capital Market - Live News